Business
Expansion into the US
Expansion into the US.
About this update from Proteome Sciences Plc
[{"type":"text","content":"\n\n12 May 2023\n \n \nProteome Sciences plc\n(\"Proteome Sciences\" or the \"Company\")\n \nProteome Sciences expands into the US: New Facility to open in San Diego\n \nProteome Sciences plc is pleased to announce the expansion of its proteomics services into the United States of America (\"US\"). A state of the art facility will be based in San Diego, California, to provide easy access to the established and growing pharmaceutical and biotechnology proteomics services requirements across the US and, in particular, the research hubs on the west coast. The Company's subsidiary, Proteome Sciences US Inc, has commenced staff recruitment and the new facility is expected to be fully operational in the fourth quarter of 2023.\n \nCommenting on the new laboratory, Dr. Ian Pike, Chief Scientific Officer and President of Proteome Sciences US Inc. said \"This is a major development for Proteome Sciences, building on the strong foundations of our services business in Europe. Whilst we already have an excellent customer base in the US, concerns over shipping costs, timing delays and customs delays have restricted the volume of orders that could be processed. We will now be able to provide a more accessible service to the rapidly growing pharma/biotech community across the US as the demand for proteomics services continues to expand.\"\n \nDr. Mariola Söhngen, Chief Executive Officer of Proteome Sciences plc, added \"Internationalisation is a key element of our growth strategy. With a major part of our service and reagent business already focused over there, it is a logical step to establish our own facility for customers in the US. This is a real milestone for Proteome Sciences and we are looking forward to improving our service to the US marketplace with the San Diego facility opening later this year. \"\n \n \nFor further information:\n\n\n\n\n \nProteome Sciences plc\n\n\n\n\nDr. Mariola Soehngen, Chief Executive Officer\nDr. Ian Pike, Chief Scientific Officer\n\n\nTel: +44 (0)20 7043 2116\n\n\n \n\n\n\n\nRichard Dennis, Chief Commercial Officer\nAbdelghani Omari, Chief Financial Officer\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\nAllenby Capital Limited (Nominated Adviser & Broker) \n\n\n \n\n\n\n\nJohn Depasquale / Jeremy Porter (Corporate Finance)\...